A
53.60
-3.05 (-5.38%)
Previous Close | 56.65 |
Open | 57.50 |
Volume | 875,926 |
Avg. Volume (3M) | 675,095 |
Market Cap | 2,944,998,400 |
Price / Sales | 28.11 |
Price / Book | 6.84 |
52 Weeks Range |
Profit Margin | -99.45% |
Operating Margin (TTM) | -348.17% |
Diluted EPS (TTM) | -2.00 |
Quarterly Revenue Growth (YOY) | -75.80% |
Total Debt/Equity (MRQ) | 11.89% |
Current Ratio (MRQ) | 4.78 |
Operating Cash Flow (TTM) | -83.47 M |
Levered Free Cash Flow (TTM) | 15.04 M |
Return on Assets (TTM) | -11.19% |
Return on Equity (TTM) | -22.84% |
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Mixed |
Biotechnology (Global) | Mixed | Mixed | |
Stock | Arcellx, Inc. | Mixed | Bullish |
AIStockmoo Score
0.7
Analyst Consensus | NA |
Insider Activity | NA |
Price Volatility | 4.5 |
Technical Moving Averages | 0.0 |
Technical Oscillators | -2.5 |
Average | 0.67 |
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Growth |
% Held by Insiders | 2.32% |
% Held by Institutions | 107.57% |
No data within this time range.
No data within this time range.
Date | Type | Details |
---|---|---|
20 Mar 2025 | Announcement | Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors |
27 Feb 2025 | Announcement | Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights |
26 Feb 2025 | Announcement | Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |